title: A novel oxidized low-density lipoprotein marker, serum amyloid A-LDL, is associated with obesity and the metabolic syndrome.
abstract: BACKGROUND
  The putative association between the novel oxidized low-density lipoprotein markers, serum amyloid A-LDL (SAA-LDL) and alpha1-antitrypsin-LDL (AT-LDL), and obesity and the metabolic syndrome (MetS) has not been previously studied. In the present report, we investigated the levels of SAA-LDL and AT-LDL in relation to the components of the MetS. We also assessed the effect of weight reduction therapy on serum SAA-LDL and AT-LDL levels among obese subjects.
  
  
  METHODS
  The study population included 421 obese Japanese outpatients (185 men and 236 women, mean age: 51.1 years) enrolled in the multicenter Japan Obesity and Metabolic Syndrome Study (JOMS). The novel oxidized low-density lipoprotein markers, serum SAA-LDL and AT-LDL, were measured in all participants.
  
  
  RESULTS
  Circulating SAA-LDL levels were independently associated with the presence and the number of components of the MetS. SAA-LDL levels were also significantly and independently correlated with high-sensitivity C-reactive protein. Notably, successful weight reduction resulted in a significant decrease in circulating SAA-LDL concentrations. Levels of AT-LDL were not associated with the MetS.
  
  
  CONCLUSIONS
  We documented, for the first time, that serum SAA-LDL levels correlate positively with the number of components of the MetS and weight reduction. Whether SAA-LDL may be involved in the pathophysiology of MetS and atherosclerosis deserves further investigation.
authors.affiliation: Division of Preventive Medicine, Clinical Research Institute for Endocrine Metabolic Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan. kazukotani@jichi.ac.jp
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Kotani
authors.forename: Noriko
authors.initials: N
authors.lastname: Satoh
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Kato
authors.forename: Rika
authors.initials: R
authors.lastname: Araki
authors.forename: Kazunori
authors.initials: K
authors.lastname: Koyama
authors.forename: Taiichiro
authors.initials: T
authors.lastname: Okajima
authors.forename: Makito
authors.initials: M
authors.lastname: Tanabe
authors.forename: Mariko
authors.initials: M
authors.lastname: Oishi
authors.forename: Hajime
authors.initials: H
authors.lastname: Yamakage
authors.forename: Kazunori
authors.initials: K
authors.lastname: Yamada
authors.forename: Masakazu
authors.initials: M
authors.lastname: Hattori
authors.forename: Akira
authors.initials: A
authors.lastname: Shimatsu
mesh_terms: D000328:Adult; D000368:Aged; D044466:Asian People; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D004038:Diet, Reducing; D002149:Energy Intake; D015444:Exercise; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000208:ethnology; D008875:Middle Aged; D009765:Obesity / Q000097:blood* / Q000208:ethnology / Q000628:therapy; D010045:Outpatients; D040242:Risk Reduction Behavior; D000685:Serum Amyloid A Protein / Q000032:analysis*; D016896:Treatment Outcome; D015431:Weight Loss; D000515:alpha 1-Antitrypsin / Q000097:blood
chemical_list: D015415:Biomarkers; D008077:Lipoproteins, LDL; C043392:SERPINA1 protein, human; D000685:Serum Amyloid A Protein; D000515:alpha 1-Antitrypsin; C099252:oxidized low density lipoprotein; D002097:C-Reactive Protein